Skip to content

Study of siddha drug Vaatha choornam (internal) and Vaatha mega narayana ennai (External) in the treatment of Rheumatoid arthritis(joint pain) (Valiazhal keelvayu)

Preclinical and clinical study of siddha drugs Vaatha chooranam (internal) and Vaatha mega narayana ennai (external) in the treatment of Vali Azhal keel vayu(Rheumatoid Arthritis)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/05/008594
Enrollment
40
Registered
2017-05-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Vali Azhal Keel Vayu (Rheumatoid arthritis)

Interventions

Intervention1: Muddakku vatha choornam (internal) and vatha mega Narayana ennai(external): 2 gm of Muddakku vatha choornam administered orally twice a day with honey for a period of 48 days. Control I

Sponsors

Ayothidoss pandithar hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age: 20- 60 years 2) Sex: Both male and female 3) Any of the following three symptoms Pain and swelling in three or more joint Morning Stiffness Rheumatoid factor positive Deformities like Swan neck and Buttton hole deformity Rheumatoid nodules 4) Symmetrical joints involvement 5) patient willing to undergo laboratory Investigation 6) Patient willing to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Pregnancy and lactation 2) Tubercular arthritis 3) Gouty arthritis 4) Diabetic Mellitus 5) Malignant Hypertension 6) Any other systemic illness

Design outcomes

Primary

MeasureTime frame
Rheumatoid arthritis is diagnosed by European League against rheumatism (EULAR)and prognosis is assessed by modified health assessment questionnaire (MHAQ) Reduction of pain is assessed before and after treatment by Universal pain assessment scale using Questionnaire Improvement in restriction of movements is assessed by restricted movements assessment scaleTimepoint: 48 days

Secondary

MeasureTime frame
1)Safety study of drugs Muddakku vatha choornam 2)Analytical study of drug muddakku vatha choornamTimepoint: 48 days

Countries

India

Contacts

Public ContactDR NJ Muthukumar

National Institute of Siddha

njmuthu@hotmail.com9962006843

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026